A New Test Could Save Arthritis Patients Time, Money, and Pain. But Will It Be Used?

SAN DIEGO Erinn Maury knew Remicade wasnt the right drug for Patti Schulte, a rheumatoid arthritis patient the physician saw at her Millersville, Maryland, practice. Schultes swollen, painful joints hadnt responded to Enbrel or Humira, two drugs in the same class.

This story also ran on NPR. It can be republished for free.

But the insurer insisted, so Schulte went on Remicade. It didnt work either.

Whats more, Schulte suffered a severe allergic reaction to the infusion therapy, requiring a heavy dose of prednisone, a steroid with grave side effects if used at high doses for too long.

After 18 months, her insurer finally approved Maurys drug of choice, Orencia. By then, Schultes vertebrae, weakened by prednisone, had started cracking. She was only 60.

Schultes story of pain, drug-hopping, and insurance meddling is all too common among patients with rheumatoid arthritis, who often cycle agonizingly through half a dozen drugs in search of one that provides a measure of relief. Its also a story of how doctors are steered by pharmacy benefit managers the middlemen of the drug market as well as by insurers.

Once people with inflammatory conditions such as rheumatoid arthritis reach a certain stage, the first prescription offered is typically Humira, the best-selling drug in history, and part of a class known as tumor necrosis factor inhibitors, or TNFis, which fail to significantly help about half of the patients who take it.

We practice rheumatology without any help, said Vibeke Strand, a rheumatologist and adjunct clinical professor at Stanford. She bemoaned the lack of tools available to choose the right drug while bristling at corporate intervention in the decision. We are told by the insurer what to prescribe to the patient. After they fail methotrexate, its a TNF inhibitor, almost always Humira. And thats not OK.

If theres a shred of hope in this story, its that a blood test, PrismRA, may herald an era of improved care for patients with rheumatoid arthritis and other autoimmune conditions. But first, it must be embraced by insurers.

PrismRA employs a predictive model that combines clinical factors, blood tests, and 19 gene patterns to identify the roughly 60% of patients who are very unlikely to respond to a TNFi drug.

Over the past 25 years, drug companies have introduced five new classes of autoimmune drugs. TNFis were the first to market, starting in the late 1990s. Email Sign-Up

Subscribe to KFF Health News' free Morning Briefing. Your Email Address Sign Up

Some 1.3 million Americans have rheumatoid arthritis, a disease in which a persons immune system attacks their joints, causing crippling pain and, if improperly treated, disfigurement. The newer drugs, mostly so-called biologics, are also used by some of the 25 million or more Americans with other autoimmune diseases, such as lupus, Crohns disease, and psoriasis. Typically costing tens of thousands of dollars annually, the drugs are prescribed after a patient fails to respond to older, cheaper drugs like methotrexate.

Until recently, rheumatologists have had few ways to predict which of the new drugs would work best on which patients. Often, its a coin flip whether I prescribe drug A or B, said Jeffrey Curtis, a rheumatology professor at the University of Alabama-Birmingham.

Yet about 90% of the patients who are given one of these advanced drugs start on a TNFi, although theres often no reason to think a TNFi will work better than another type.

Under these puzzling circumstances, its often the insurer rather than the doctor who chooses the patients drug. Insurers lean toward TNFis such as adalimumab, commonly sold as brand-name Humira, in part because they get large rebates from manufacturers for using them. Although the size of such payments is a trade secret, AbbVie is said to be offering rebates to insurers of up to 60% of Humiras price. That has enabled it to control 98.5% of the U.S. adalimumab market, even though it has eight biosimilar competitors.

PrismRAs developer, Scipher Medicine, has provided more than 26,000 test results, rarely covered by insurance. But on Oct. 15, the Centers for Medicare & Medicaid began reimbursing for the test, and its use is expected to rise. At least two other companies are developing drug-matching tests for rheumatoid arthritis patients.

Although critics say PrismRA is not always useful, it is likely to be the first in a series of diagnostics anticipated over the next decade that could reduce the time that autoimmune disease patients suffer on the wrong drug.

Academics, small biotechs, and large pharmaceutical companies are investing in methods to distinguish the biological pathways involved in these diseases, and the best way to treat each one. This approach, called precision medicine, has existed for years in cancer medicine, in which its routine to test the genetics of patients tumors to determine the appropriate drug treatment.

You wouldnt give Herceptin to a breast cancer patient without knowing whether her tumor was HER2-positive, said Costantino Pitzalis, a rheumatology professor at the William Harvey Research Institute in London. He was speaking before a well-attended session at an American College of Rheumatology conference in San Diego in November. Why do we not use biopsies or seek molecular markers in rheumatoid arthritis?

Its not only patients and doctors who have a stake in which drugs work best for a given person.

When Remicade failed and Schulte waited for the insurer to approve Orencia, she insisted on keeping her job as an accountant. But as her prednisone-related spinal problems worsened, Schulte was forced to retire, go on Medicaid, and seek disability, something she had always sworn to avoid.

Now taxpayers, rather than the insurer, are covering Schultes medical bills, Maury noted.

Precision medicine hasnt seemed like a priority for large makers of autoimmune drugs, which presumably have some knowledge of which patients are most likely to benefit from their drugs, since they have tested and sold millions of doses over the years. By offering rebate incentives to insurers, companies like AbbVie, which makes Humira, can guarantee theirs are the drugs of choice with insurers.

If you were AbbVie, Curtis said, why would you ever want to publish data showing whos not going to do well on your drug, if, in the absence of the test, everyone will start with your drug first? Humira, the injectable rheumatoid arthritis treatment, is part of a class of drugs which fail to significantly help about half of the patients who take it. About 1.3 million Americans have the disease in which a persons immune system attacks their joints.(Bloomberg/Getty Images)

What Testing Could Do

Medicare and commercial insurers havent yet set a price for PrismRA, but it could save insurers thousands of dollars a year for each patient it helps, according to Krishna Patel, Sciphers associate director of medical affairs.

If the test cost $750, I still only need it once, and it costs less than a month of whatever drug is not going to work very well for you, said Curtis, a co-author of some studies of the test. The economics of a biomarker thats anything but worthless is pretty favorable because our biologics and targeted drugs are so expensive.

Patients are enthusiastic about the test because so many have had to take TNFis that didnt work. Many insurers require patients to try a second TNFi, and sometimes a third.

Jen Weaver, a patient advocate and mother of three, got little benefit from hydroxychloroquine, sulfasalazine, methotrexate, and Orencia, a non-TNFi biologic therapy, before finding some relief in another, Actemra. But she was taken off that drug when her white blood cells plunged, and the next three drugs she tried all TNFis caused allergic reactions, culminating with an outbreak of pus-filled sores. Another drug, Otezla, eventually seemed to help heal the sores, and shes been stable on it since in combination with methotrexate, Weaver said.

What is needed is to substantialy shorten this trial-and-error period for patients, said Shilpa Venkatachalam, herself a patient and the director of research operations at the Global Healthy Living Foundation. Theres a lot of anxiety and frustration, weeks in pain wondering whether a drug is going to work for you and what to do if it doesnt. A survey by her group found that 91% of patients worried their medications would stop working. And there is evidence that the longer it takes to resolve arthritis symptoms, the less chance they will ever stop.

How insurers will respond to the availability of tests isnt clear, partly because the arrival of new biosimilar drugs essentially generic versions are making TNFis cheaper for insurance plans. While Humira still dominates, AbbVie has increased rebates to insurers, in effect lowering its cost. Lower prices make the PrismRA test less appealing to insurers, since widespread use of the test could cut TNFi prescriptions by up to a third.

However, rheumatologist John Boone in Louisville, Kentucky, found to his surprise that insurers mostly accepted alternative prescriptions for 41 patients whom the test showed unlikely to respond to TNFis as part of a clinical trial. Boone receives consulting fees from Scipher.

Although the test didnt guarantee good outcomes, he said, the few patients given TNFis despite the test results almost all did poorly on that regimen.

Scientists from AbbVie, which makes several rheumatology drugs in addition to Humira, presented a study at the San Diego conference examining biomarkers that might show which patients would respond to Rinvoq, a new immune-suppressing drug in a class known as the JAK inhibitors. When asked about its use of precision medicine, AbbVie declined to comment.

Over two decades, Humira has been a blockbuster drug for AbbVie. The company sold more than $3.5 billion worth of Humira in the third quarter of 2023, 36% less than a year ago. Sales of Rinvoq, which AbbVie is marketing as a treatment for patients failed by Humira and its class, jumped 60% to $1.1 billion.

What Patients Want

Shannan OHara-Levi, a 38-year-old in Monroe, New York, has been on scores of drugs and supplements since being diagnosed with juvenile arthritis at age 3. Shes been nauseated, fatigued, and short of breath and has suffered allergic reactions, but she says the worst part of it was finding a drug that worked and then losing access because of insurance. This happened shortly after she gave birth to a daughter in 2022, and then endured intense joint pain.

If I could take a blood test that tells me not to waste months or years of my life absolutely, she said. If I could have started my current drug last fall and saved many months of not being able to engage with my baby on the floor absolutely.

Arthur Allen: ArthurA@kff.org, @ArthurAllen202 Related Topics Health Care Costs Health Industry Pharmaceuticals Autoimmune Diseases Drug Costs Prescription Drugs Contact Us Submit a Story Tip